1,721,032 research outputs found
Update of carcinoembryonic antigen radioimmunotherapy with (131)supercript stopI-Labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group
No full textBackground: We tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival. Resection of LM from colorectal cancer is the standard of care in this setting, yet two thirds will eventually relapse, and adjuvant systemic chemotherapy has failed to improve survival. Methods: Twenty-three patients who underwent R0 resection for LM of colorectal cancer received a dose of 40 to 60 mCi/m(2) I-131-labetuzumab, a humanized monoclonal antibody against carcinoembryonic antigen. Safety (n = 23), disease-free survival, and overall survival (n = 19) were analyzed, and efficacy was then compared retrospectively with a similar contemporaneous group of control patients (n = 19) treated at the same institution during the same time period but without RAIT. Results: At a median follow-up of 91 months (95% confidence interval [CI], 68.0 months to infinity), the median overall survival for RAIT patients was 58.0 months (95% CI, 55.0 months to infinity), versus 31.0 months (95% CI, 26.0 months to infinity) at a 51-month median follow-up for the controls (P = .032). The median disease-free survival for RAIT patients was 18.0 months (95% CI, 11.0-31.0 months), versus 12.0 months (95% CI, 6.5-27.0 months) for the controls (P = .565). Corresponding survival rates (Kaplan-Meier analyses) were estimated to be 94.7% at 1 year, 78.9% at 2 years, 68.4% at 3 years, and 42.1% at 5 years with RAIT and 94.7%, 68.4%, 36.8%, and 15.8%, respectively, for the controls. RAIT was beneficial independently of bilobar involvement, size and number of LM, or resection margins. Transient myelosuppression was the principal adverse effect. Conclusions: This first evidence of a promising survival advantage of adjuvant RAIT after long-term follow-up of colorectal cancer patients given salvage resection of LM warrants confirmation in a prospective randomized trial
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
No full textThis article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers. © 2006 by American Society of Clinical Oncology
Repeated anti-cea-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase-II-study) versus a single dose rait post-salvage resection of Colorectal Liver Metastases (CRC-LM)
No full textRepeated versus single dose anti-CEA radioimmunotherapy (RIT) with iodine-131-labetuzumab after R0 resection for colorectal liver metastases (CRC-LM)
No full textRepeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM)
No full textRepeated anti-cea-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase-II-study) versus a single dose rait post-salvage resection of Colorectal Liver Metastases (CRC-LM)
No full textRepeated versus single dose anti-CEA radioimmunotherapy (RIT) with iodine-131-labetuzumab after R0 resection for colorectal liver metastases (CRC-LM)
No full text- …
